Publications

Publications pour l'équipe Oncostat

Titre Publication Type Publication year Auteur
Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis journalArticle 2016 Holliday, E. B.; Kocak-Uzel, E.; Feng, L.; Thaker, N. G.; Blanchard, P.; Rosenthal, D. I.; Gunn, G. B.; Garden, A. S.; Frank, S. J.
Hypofractionation for prostate cancer: a word of caution journalArticle 2016 Bossi, A.; Blanchard, P.
Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients journalArticle 2016 Rodriguez, C.; Suciu, V.; Poterie, A.; Lacroix, L.; Miran, I.; Boichard, A.; Delaloge, S.; Deneuve, J.; Azoulay, S.; Mathieu, M. C.; Valent, A.; Michiels, S.; Arnedos, M.; Vielh, P.
Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial journalArticle 2016 Krol, A.; Ferrer, L.; Pignon, J. P.; Proust-Lima, C.; Ducreux, M.; Bouche, O.; Michiels, S.; Rondeau, V.
Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block? journalArticle 2016 Ducreux, M.; Pignon, J. P.
New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study journalArticle 2016 Bayar, M. A.; Le Teuff, G.; Michiels, S.; Sargent, D. J.; Le Deley, M. C.
The frequency of cancer in France: Most recent data and trends journalArticle 2017 Ribassin-Majed, L.; Le-Teuff, G.; Hill, C.
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial journalArticle 2017 Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial journalArticle 2017 Belin, L.; Kamal, M.; Mauborgne, C.; Plancher, C.; Mulot, F.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Trédan, O.; Ricci, F.; Alt, M.; Loirat, D.; Sablin, M. P.; Paoletti, X.; Servois, V.; Le Tourneau, C.
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients journalArticle 2017 Boros, A.; Lacroix, L.; Lacas, B.; Adam, J.; Pignon, J. P.; Caramella, C.; Planchard, D.; de Montpreville, V.; Deutsch, E.; Levy, A.; Besse, B.; Le Pechoux, C.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
In Regard to Arthurs et al journalArticle 2017 Blanchard, P.; Garden, A. S.
Use of Low-Thrombin Fibrin Sealant Glue After Axillary Lymphadenectomy for Breast Cancer to Reduce Hospital Length and Seroma journalArticle 2017 Conversano, A.; Mazouni, C.; Thomin, A.; Gaudin, A.; Fournier, M.; Rimareix, F.; Bonastre, J.
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? journalArticle 2017 Blanchard, P.; Bossi, A.; Fizazi, K.
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial journalArticle 2017 Besse, B.; Mazières, J.; Ribassin-Majed, L.; Barlesi, F.; Bennouna, J.; Gervais, R.; Moreau, L.; Berard, H.; Debieuvre, D.; Molinier, O.; Moro-Sibilot, D.; Souquet, P. J.; Jacquot, S.; Petit, L.; Lena, H.; Pignon, J. P.; Lacas, B.; Morin, F.; Milleron, B.; Zalcman, G.; Soria, J. C.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium journalArticle 2017 Bautista, F.; Moreno, L.; Marshall, L.; Pearson, A. D. J.; Geoerger, B.; Paoletti, X.
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study journalArticle 2017 Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L.
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study) journalArticle 2017 Fresneau, Brice; Hackshaw, A.; Hawkins, D. S.; Paulussen, M.; Anderson, J. R.; Judson, I.; Litière, S.; Dirksen, U.; Lewis, I.; van den Berg, H.; Gaspar, N.; Gelderblom, H.; Whelan, J.; Boddy, A. V.; Wheatley, K.; Pignon, J. P.; De Vathaire, F.; Le Deley, M. C.; Le Teuff, G.
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort journalArticle 2017 Blanchard, P.; Davis, J. W.; Frank, S. J.; Kim, J.; Pettaway, C. A.; Pugh, T. J.; Pisters, L. L.; Ward, J. F.; Choi, S.; Chapin, B. F.; Hoffman, K.; Navai, N.; Achim, M.; McGuire, S. E.; Matin, S. F.; Nguyen, Q.; Mahmood, U.; Graber, W. J.; Chen, H. C.; Wang, X.; Kuban, D. A.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time? journalArticle 2017 Bossi, A.; Mottet, N.; Blanchard, P.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors journalArticle 2017 Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C.
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab journalArticle 2017 Chaput, N.; Lepage, P.; Coutzac, C.; Soularue, E.; Le Roux, K.; Monot, C.; Boselli, L.; Routier, E.; Cassard, L.; Collins, M.; Vaysse, T.; Marthey, L.; Eggermont, A.; Asvatourian, V.; Lanoy, E.; Mateus, C.; Robert, C.; Carbonnel, F.
Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice journalArticle 2017 Berdelou, A.; Borget, I.; Godbert, Y.; Nguyen, T.; Garcia, M. E.; Chougnet, C. N.; Ferru, A.; Buffet, C.; Chabre, O.; Huillard, O.; Leboulleux, S.; Schlumberger, M.
Radiation-induced neurocognitive dysfunction in head and neck cancer patients journalArticle 2017 De Felice, F.; Blanchard, P.
Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment journalArticle 2017 Annede, P.; Gouy, S.; Mazeron, R.; Bentivegna, E.; Maroun, P.; Petit, C.; Dumas, I.; Leary, A.; Genestie, C.; Lhomme, C.; Deutsch, E.; Morice, P.; Pautier, P.; Haie-Meder, C.; Chargari, C.
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort journalArticle 2017 Blanchard, P.; Davis, J. W.; Frank, S. J.; Kim, J.; Pettaway, C. A.; Pugh, T. J.; Pisters, L. L.; Ward, J. F.; Choi, S.; Chapin, B. F.; Hoffman, K.; Navai, N.; Achim, M.; McGuire, S. E.; Matin, S. F.; Nguyen, Q.; Mahmood, U.; Graber, W. J.; Chen, H. C.; Wang, X.; Kuban, D. A.
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents journalArticle 2017 Azan, A.; Caspers, P. J.; Bakker Schut, T. C.; Roy, S.; Boutros, C.; Mateus, C.; Routier, E.; Besse, B.; Planchard, D.; Seck, A.; Kamsu Kom, N.; Tomasic, G.; Koljenovic, S.; Noordhoek Hegt, V.; Texier, M.; Lanoy, E.; Eggermont, A. M.; Paci, A.; Robert, C.; Puppels, G. J.; Mir, L. M.
Statistical approaches for evaluating body composition markers in clinical cancer research journalArticle 2017 Bayar, M. A.; Antoun, S.; Lanoy, E.
Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful? journalArticle 2017 Daroles, J.; Borget, I.; Suciu, V.; Mazouni, C.; Delaloge, S.; Balleyguier, C.
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients journalArticle 2017 Boros, A.; Lacroix, L.; Lacas, B.; Adam, J.; Pignon, J. P.; Caramella, C.; Planchard, D.; de Montpreville, V.; Deutsch, E.; Levy, A.; Besse, B.; Le Pechoux, C.
Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment journalArticle 2017 Annede, P.; Gouy, S.; Mazeron, R.; Bentivegna, E.; Maroun, P.; Petit, C.; Dumas, I.; Leary, A.; Genestie, C.; Lhomme, C.; Deutsch, E.; Morice, P.; Pautier, P.; Haie-Meder, C.; Chargari, C.
In Regard to Arthurs et al journalArticle 2017 Blanchard, P.; Garden, A. S.
Diagnosis of systemic inflammatory diseases among patients admitted for acute pericarditis with pericardial effusion journalArticle 2017 Assayag, M.; Abbas, R.; Chanson, N.; Perozziello, A.; Ducrocq, G.; Alexandra, J. F.; Dossier, A.; Papo, T.; Sacre, K.
Burnout among young European oncologists: a call for action journalArticle 2017 Blanchard, P.
Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data journalArticle 2017 Yin, Jun; Paoletti, Xavier; Sargent, Daniel J; Mandrekar, Sumithra J
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial journalArticle 2017 Besse, B.; Mazières, J.; Ribassin-Majed, L.; Barlesi, F.; Bennouna, J.; Gervais, R.; Moreau, L.; Berard, H.; Debieuvre, D.; Molinier, O.; Moro-Sibilot, D.; Souquet, P. J.; Jacquot, S.; Petit, L.; Lena, H.; Pignon, J. P.; Lacas, B.; Morin, F.; Milleron, B.; Zalcman, G.; Soria, J. C.
Bayesian survival analysis in clinical trials: What methods are used in practice? journalArticle 2017 Brard, C.; Le Teuff, G.; Le Deley, M. C.; Hampson, L. V.